STUDI IN SILICO SIFAT FARMAKOKINETIK, TOKSISITAS, DAN AKTIVITAS IMUNOMODULATOR BRAZILEIN KAYU SECANG TERHADAP ENZIM 3-CHYMOTRYPSIN-LIKE CYSTEINE PROTEASE CORONAVIRUS
Article Sidebar
Main Article Content
Abstract
The 3-chymotrypsin-like cysteine ??protease (3CLpro) is an enzyme that control replication of the coronavirus life cycle. The 3CLpro is a biological target that will interact with drugs. Brazilein is a major compound found in secang wood that used as an immunomodulator. This study aims to predict the immunomodulatory activity of the brazilein against the 3CLpro using in silico method, with curcumin as comparative compound. In silico test was used to predict immunomodulatory activity by docking using the Molegro Virtual Docke. Receptors used are 3CLpro, PDB code: 6M2N, with ligand 3WL_401[C]. pkCSM online program used to predict pharmacokinetic properties (ADME) and toxicity from brazilein and curcumin. Data was analyzed by comparing the docking bond energy between brazilein, ligands and curcumin at the target receptor. The lower the ligand bond energy, the more stable the bond is formed. The results of the in silico test showed that the ligand bond energy = -83,1153kcal/mol, brazilein = -82.0583kcal/mol, and curcumin = -115.852kcal/mol. Brazilein has lower potential as an immunomodulator than ligands and curcumin. The results of the in silico test using the pkCSM online program showed that the brazilein compound had good pharmacokinetic properties and low toxicity.
Article Details
JoIMedLabS uses license under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-SA 4.0).
The licensing description below is copied from the Creative Commons website:
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.